170 related articles for article (PubMed ID: 15308606)
41. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
[TBL] [Abstract][Full Text] [Related]
42. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
[TBL] [Abstract][Full Text] [Related]
43. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
Wingard JR; Kubilis P; Lee L; Yee G; White M; Walshe L; Bowden R; Anaissie E; Hiemenz J; Lister J
Clin Infect Dis; 1999 Dec; 29(6):1402-7. PubMed ID: 10585786
[TBL] [Abstract][Full Text] [Related]
44. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
45. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B.
Strenger V; Meinitzer A; Donnerer J; Hofer N; Dornbusch HJ; Wanz U; Seidel MG; Sperl D; Lackner H; Schwinger W; Sovinz P; Benesch M; Urban C
J Antimicrob Chemother; 2014 Sep; 69(9):2522-6. PubMed ID: 24891430
[TBL] [Abstract][Full Text] [Related]
46. Proteinuria lowers the risk of amphotericin B-associated hypokalaemia.
Mohan S; Ahmed S; Alimohammadi B; Jaitly M; Cheng JT; Pogue VA
J Antimicrob Chemother; 2007 Sep; 60(3):690-3. PubMed ID: 17597057
[TBL] [Abstract][Full Text] [Related]
47. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
Amaral AC; Bocca AL; Ribeiro AM; Nunes J; Peixoto DL; Simioni AR; Primo FL; Lacava ZG; Bentes R; Titze-de-Almeida R; Tedesco AC; Morais PC; Felipe MS
J Antimicrob Chemother; 2009 Mar; 63(3):526-33. PubMed ID: 19151037
[TBL] [Abstract][Full Text] [Related]
48. Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.
Stanzani M; Vianelli N; Cavo M; Maritati A; Morotti M; Lewis RE
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28607011
[TBL] [Abstract][Full Text] [Related]
49. Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients.
Villani P; Regazzi MB; Maserati R; Viale P; Alberici F; Giacchino R
Arzneimittelforschung; 1996 Apr; 46(4):445-9. PubMed ID: 8740098
[TBL] [Abstract][Full Text] [Related]
50. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients.
Reed A; Herndon JB; Ersoz N; Fujikawa T; Schain D; Lipori P; Hemming A; Li Q; Shenkman E; Vogel B
Liver Transpl; 2007 Dec; 13(12):1743-50. PubMed ID: 18044769
[TBL] [Abstract][Full Text] [Related]
51. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
Schuler U; Bammer S; Aulitzky WE; Binder C; Böhme A; Egerer G; Sandherr M; Schwerdtfeger R; Silling G; Wandt H; Glasmacher A; Ehninger G
Onkologie; 2007 Apr; 30(4):185-91. PubMed ID: 17396041
[TBL] [Abstract][Full Text] [Related]
53. Invasive pulmonary aspergillosis in solid organ and bone marrow transplant recipients.
Trullas JC; Cervera C; Benito N; de la Bellacasa JP; Agustí C; Rovira M; Mas A; Navasa M; Cofan F; Ricart MJ; Pérez-Villa F; Moreno A
Transplant Proc; 2005 Nov; 37(9):4091-3. PubMed ID: 16386634
[TBL] [Abstract][Full Text] [Related]
54. Study of renal safety in amphotericin B lipid complex-treated patients.
Alexander BD; Wingard JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
[TBL] [Abstract][Full Text] [Related]
55. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
[TBL] [Abstract][Full Text] [Related]
56. Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan.
Chen CY; Kumar RN; Feng YH; Ho CH; You JY; Liao CC; Tseng CH; Mavros P; Gerth WC; Chen YC
J Antimicrob Chemother; 2006 Jun; 57(6):1181-8. PubMed ID: 16595642
[TBL] [Abstract][Full Text] [Related]
57. Nephrotoxicity in the setting of invasive fungal diseases.
Ullmann AJ
Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
[TBL] [Abstract][Full Text] [Related]
58. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
59. [Amphotericin B: the end of an era].
Oude Lashof AM; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
[TBL] [Abstract][Full Text] [Related]
60. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
